| Literature DB >> 29529485 |
Ryan H Tomlinson1, Lisa G Harrison1, Elizabeth A Meals1, John P DeVincenzo2.
Abstract
Entities:
Mesh:
Year: 2018 PMID: 29529485 PMCID: PMC7128593 DOI: 10.1016/j.jcv.2018.03.002
Source DB: PubMed Journal: J Clin Virol ISSN: 1386-6532 Impact factor: 3.168
Subject Entry Criteria. This table outlines the strict inclusion and exclusion criteria used to screen for asymptomatic, healthy adults, and was derived from previous human respiratory syncytial virus challenge models [[3], [4]]. A complete list of selection criteria can be found in supplementary materials [[3], [4]].
| Variables |
|---|
| Inclusion |
| 1. Healthy males and females (no clinically significant abnormalities identified by a detailed medical history, full physical examination) |
| 2. 18–45 years of age |
| 3. Body mass index of 18–33 kg/m2; total body weight ≥ 50 kg |
| 4. Low serum RSV neutralization titers |
| Exclusion |
| 1. Symptoms of hay fever |
| 2. Abnormal clinically significant laboratory test (complete metabolic panel, urinalysis, complete blood count) or ECG |
| 3. Significant respiratory symptoms suggestive of respiratory infection within 14 days |
| 4. Use (within 7 days) of any medication or other product (prescription or OTC), for symptoms of hay fever, rhinitis, nasal congestion, or respiratory tract infection, with the exception of limited amounts of paracetamol |
| 5. Systemic glucocorticoids, antiviral drugs, and immunoglobulins, or any other cytotoxic or immunosuppressive drug within 6 months prior to dosing; receipt of any systemic chemotherapy agent at any time |
| 6. Any significant acute or chronic, uncontrolled medical illness associated with increased risk of complications of respiratory viral illness |
| 7. Adult onset of asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, reactive airway disease, or any chronic lung condition of any etiology |
| 8. Autoimmune disease or known impaired immune responsiveness (of any cause) |
| 9. Human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infected |
| 10. Significant abnormality altering the anatomy of the nose or nasopharynx |
| 11. Any clinically significant history of epistaxis |
| 12. Any nasal or sinus surgery within 6 months |
| 13. Tobacco use at any time (≥ total 10-pack year history [i.e. 1 pack a day for 10 years]) |
| 14. Abnormal pulmonary function (spriometry) |
| 15. Pregnant or nursing or male subjects whose partners are pregnant |
| 16. Health care workers with patient contact |
| 17. Presence of a household member or close contact with someone (for 2 weeks following study testing) who: is < 3 years of age, has any known immunodeficiency, is receiving immunosuppressant medications, is undergoing or soon to undergo cancer chemotherapy, has been diagnosed with emphysema or COPD, is elderly residing in a nursing home, has severe lung disease, or has received a transplant (bone marrow or solid organ) |
Respiratory Virus Detection Frequency. The results of a total of 190 subjects were evaluated (one sample collection per subject). Two different PCR assays analyzed slightly different sets of respiratory viruses [Genmark (Carlsbad, CA); Prodesse ProFLU™+ (GenProbe, San Diego, CA)]. Manufacturer procedure assays were performed using a certified clinical molecular diagnostics laboratory (Methodist LeBonheur Molecular Diagnostics Laboratory, Memphis, TN). All assays employed closed, never-opened amplicon tubes, and counter-current sample flow – workflow directionality and other contamination prevention procedures. 124 subjects were analyzed by ProFLU™+ PCR (Influenza A & B, respiratory syncytial virus (RSV) A & B, human metapneumovirus (hMPV), and parainfluenza 1,2,3); sixty-six subjects were analyzed by Genmark PCR (detecting the same viruses as ProFLU™ + but also detecting parainfluenza 4, rhinovirus, human coronavirus 229E, NL63, HKU1 and OC43, and adenovirus). Subjects sampled after the start of the H1N1 pandemic flu were analyzed by detection chemistries, which included this pathogen.
| Assay | Month Range | Number of subjects (N) | % Pos. Freq | Type of virus N(%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Influenza | RSV | hMPV | HCoV | Rhino | Adeno | Para | ||||
| Genmark® PCR | 5/15 → 8/15 | 66 | 12 | 0/66 (0) | 0/66 (0) | 0/66 (0) | 0/66(0) | 8/66 (12) | 0/66(0) | 0/66 (0) |
| ProFLU™+PCR | 11/06 → 11/07 | 124 | 0 | 0/124 (0) | 0/124(0) | 0/124 (0) | – | – | – | 0/124(0) |
| Total | 190 | 12 | 0/190 (0) | 0/190(0) | 0/190(0) | 0/66(0) | 8/66(12) | 0/66(0) | 0/190(0) | |
Influenza PCR subtypes include: influenza A (H1 and H3) and influenza B. Genmark detects 2009 H1N1. The studies using ProFLU™ + assay were performed prior to 2009 H1N1 pandemic.
Numbers represent combined frequencies for RSV A and RSV B, which are separate PCRs.
Human coronavirus subtypes include: 229E, NL63, HKU1, and OC43.
Parainfluenza virus subtypes include: 1, 2, 3, and 4.
Adenovirus subtypes include: B/E and C.
ProFLU ™+ PCR assay includes two separate collection time points, a cohort of 36 samples were collected from 28 Nov. 2006–26 Feb. 2007 and a second cohort of 88 samples were collected from 19 June 2007–15 Nov. 2007.